<DOC>
	<DOCNO>NCT02468232</DOCNO>
	<brief_summary>The purpose study assess effect LCZ696 target dose 200 mg b.i.d . compare enalapril 10 mg b.i.d. , addition background heart failure ( HF ) treatment , delay time first occurrence either cardiovascular ( CV ) death HF hospitalization event Japanese patient stable chronic heart failure ( CHF ) , New York Heart Association ( NYHA ) class II-IV reduced ejection fraction ( left ventricular ejection fraction ( LVEF ) ≤ 35 % ) .</brief_summary>
	<brief_title>Study Efficacy Safety LCZ696 Japanese Patients With Chronic Heart Failure Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Outpatients diagnosis CHF NYHA class IIIV reduce ejection fraction : LVEF ≤ 35 % Visit 1 ( local measurement , make within past 6 month use echocardiography , MUGA , CT scanning , MRI ventricular angiography also acceptable , provided subsequent measurement 35 % ) NTproBNP ≥ 600 pg/ml Visit 1 OR NTproBNP ≥ 400 pg/ml Visit 1 hospitalization HF within last 12 month ( accord central laboratory measurement ) Patients must ACEI ARB stable dose least 4 week Visit 1 . Patients must treat βblocker , unless contraindicate tolerated , stable dose least 4 week prior Visit 1 ( reason document patient report contraindication intolerance ) . An aldosterone antagonist also consider patient , take account renal function , serum potassium tolerability . If give , dose aldosterone antagonist optimize accord guideline recommendation patient tolerability , stable least 4 week prior Visit 1 . Other evidencebased therapy HF also consider e.g . cardiac resynchronization therapy implantable cardioverterdefibrillator select patient , recommend guideline . History hypersensitivity study drug drug similar chemical class , ACEIs , ARBs , NEP inhibitor well know suspect contraindication study drug . Previous documented history intolerance ACEIs ARBs . Known history angioedema . Requirement treatment ACEIs ARBs . Current acute decompensated HF ( exacerbation chronic HF manifest sign symptom may require intravenous therapy ) . Symptomatic hypotension and/or SBP &lt; 100 mmHg screen &lt; 95 mmHg end runin . Estimated GFR &lt; 30 mL/min/1.73 m2 measure Japanese formula screening , end runin &gt; 35 % decline eGFR screen end runin ( accord local measurement ) . Serum potassium &gt; 5.2 mmol/L ( mEq/L ) screen &gt; 5.4 mmol/L ( mEq/L ) end runin ( accord local measurement ) . Acute coronary syndrome , stroke , transient ischemic attack , cardiac , carotid major CV surgery , percutaneous coronary intervention ( PCI ) carotid angioplasty within 3 month prior Visit 1 . Documented untreated ventricular arrhythmia syncopal episode within 3 month prior Visit 1 . Symptomatic bradycardia second ( except asymptomatic Wenckebach block ) third degree heart block without pacemaker . Presence hemodynamically significant mitral and/or aortic valve disease , except mitral regurgitation secondary leave ventricular dilatation . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic subaortic stenosis . Presence bilateral renal artery stenosis . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>cardiovascular death</keyword>
	<keyword>hospitalization</keyword>
	<keyword>outcome study</keyword>
	<keyword>worsen heart failure</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>NYHA</keyword>
	<keyword>KCCQ</keyword>
	<keyword>HF-rEF</keyword>
</DOC>